OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chao on the Study of PD-L1 Inhibitors with NSCLC

February 24th 2023

Yvonne Chao, MD, PhD, discusses the study of various PD-L1 inhibitors in patients with non–small cell lung cancer.

Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood Cancer

February 24th 2023

Matthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.

Dr. Harding on Future Directions in the Treatment of Advanced Biliary Tract Cancers

February 24th 2023

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.

Dr. McArthur on the Implications of the ASCENT Trial in TNBC

February 24th 2023

Heather Lynn McArthur, MD, MPH, discusses the implications of the phase 3 ASCENT trial in patients with advanced triple-negative breast cancer.

Dr. Amandeep Salhotra on the Efficacy and Safety of Orca-Q in GVHD

February 24th 2023

Amandeep Salhotra, MD, discusses efficacy data from a phase 1 trial of Orca-Q in acute and chronic graft-vs-host disease.

Dr. Cortes on Better Understanding Areas of Interest in ALL

February 24th 2023

Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.

Dr. Barber on the Role of Molecular Profiling for Treatment Considerations in Endometrial Cancer

February 23rd 2023

Emma L. Barber, MD, discusses the role of molecular profiling for treatment considerations in patients with endometrial cancer.

Dr. Frank on the Rationale for CD22-Targeted CAR T-cell Therapy After CD19 Relapse in LBCL

February 23rd 2023

Matthew Frank, MD, PhD, discusses the rationale for investigating CD22-directed CAR-T cell therapy in adult patients with large B-cell lymphoma who relapsed after or were refractory to CD19-directed CAR T-cell therapy.

Dr. Patil on Unmet Needs With the Use of Immunotherapy in NSCLC

February 23rd 2023

Pradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.

Dr. Kim on Tislelizumab in Advanced ESCC

February 23rd 2023

Sunnie Kim, MD, contextualizes the use of tislelizumab as a frontline treatment option in advanced esophageal squamous cell carcinoma.

Dr. Kelly on Trials Evaluating Frontline Immunotherapy Combinations in ESCC

February 23rd 2023

Ronan J. Kelly, MD, MBA, discusses the variety of clinical trials investigating immunotherapy with or without chemotherapy in patients with esophageal squamous cell carcinoma.

Dr. Leapman on Factors Influencing the Decision to Undergo Genomic Testing in Prostate Cancer

February 23rd 2023

Michael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.

Dr. Grivas on the Real-World Study of Avelumab Maintenance in Metastatic Urothelial Carcinoma

February 23rd 2023

Petros Grivas, MD, PhD, discusses key baseline characteristics from the real-world PATRIOT II study of first-line avelumab maintenance therapy in metastatic urothelial cancer.

Dr. Harding on the Evolution of Frontline Chemotherapy Approaches in Advanced Biliary Tract Cancer

February 23rd 2023

James Harding, MD, discusses key trials contributing to the evolution of frontline chemoimmunotherapy approaches in advanced biliary tract cancer.

Dr. Kaklamani on Racial Disparities and Clinical Outcomes in the RxPONDER Trial in Breast Cancer

February 22nd 2023

Virginia Kaklamani, MD, discusses how racial disparities may affect patient outcomes and treatment expectations based on data from the RxPONDER trial in breast cancer.

Dr. Contreras on the Use of Surgical Resection in Desmoplastic Melanoma

February 22nd 2023

Carlo Contreras, MD, discusses how continued investigations in desmoplastic melanoma could better inform the use of surgical resection in select patients.

Dr. Daneshmand on Erdafitinib in NMIBC

February 22nd 2023

Siamak Daneshmand, MD, discusses findings from the interim analysis of cohort 3 of the multicohort phase 2 THOR-2 trial.

Dr. Efstathiou on Niraparib Plus Abiraterone Acetate in mCRPC

February 22nd 2023

Eleni Efstathiou, MD, PhD, discusses second interim findings from a subgroup analysis of the phase 3 MAGNITUDE trial in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Dr. Atkins on TFS Outcomes from the HCRN GU16-260 Trial in RCC

February 22nd 2023

Michael B. Atkins, MD, discusses the treatment-free survival outcomes from cohort A of the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Dr. Sridhar on the Long-Term Data from the JAVELIN Bladder 100 Trial in Advanced Urothelial Carcinoma

February 22nd 2023

Srikala Sridhar, MD, MSc, FRCPC, discusses long-term follow-up data from the phase 3 JAVELIN Bladder 100 in patients with advanced urothelial carcinoma.